HIV late presenters are at high risk of Cytomegalovirus reactivation and end-organ disease. CMV viremia has been associated with poor survival but the effect of anti-CMV treatment has not been studied in this setting.
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment
Bigliano, Paolo;Calcagno, Andrea;Audagnotto, Sabrina;Montrucchio, Chiara;Marinaro, Letizia;Alcantarini, Chiara;Di Perri, Giovanni;Bonora, Stefano
Last
2018-01-01
Abstract
HIV late presenters are at high risk of Cytomegalovirus reactivation and end-organ disease. CMV viremia has been associated with poor survival but the effect of anti-CMV treatment has not been studied in this setting.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
BiglianoArticle 26may2017.docx
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
49.26 kB
Formato
Microsoft Word XML
|
49.26 kB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
|
BiglianoArticle 26may2017.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
71.16 kB
Formato
Adobe PDF
|
71.16 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
